vs

Side-by-side financial comparison of GULFPORT ENERGY CORP (GPOR) and Sarepta Therapeutics, Inc. (SRPT). Click either name above to swap in a different company.

GULFPORT ENERGY CORP is the larger business by last-quarter revenue ($398.2M vs $369.6M, roughly 1.1× Sarepta Therapeutics, Inc.). GULFPORT ENERGY CORP runs the higher net margin — 33.3% vs -111.5%, a 144.8% gap on every dollar of revenue. On growth, GULFPORT ENERGY CORP posted the faster year-over-year revenue change (66.0% vs -42.1%). Over the past eight quarters, GULFPORT ENERGY CORP's revenue compounded faster (18.6% CAGR vs 1.4%).

Gulfport Energy Corp is a U.S.-headquartered independent oil and natural gas exploration and production company. It primarily operates in onshore resource basins including Ohio's Utica Shale and Oklahoma's SCOOP play, producing natural gas, crude oil, and natural gas liquids to supply North American industrial, utility, and commercial end markets.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

GPOR vs SRPT — Head-to-Head

Bigger by revenue
GPOR
GPOR
1.1× larger
GPOR
$398.2M
$369.6M
SRPT
Growing faster (revenue YoY)
GPOR
GPOR
+108.1% gap
GPOR
66.0%
-42.1%
SRPT
Higher net margin
GPOR
GPOR
144.8% more per $
GPOR
33.3%
-111.5%
SRPT
Faster 2-yr revenue CAGR
GPOR
GPOR
Annualised
GPOR
18.6%
1.4%
SRPT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GPOR
GPOR
SRPT
SRPT
Revenue
$398.2M
$369.6M
Net Profit
$132.4M
$-412.2M
Gross Margin
76.6%
Operating Margin
44.9%
-111.4%
Net Margin
33.3%
-111.5%
Revenue YoY
66.0%
-42.1%
Net Profit YoY
148.5%
-359.2%
EPS (diluted)
$7.98
$-3.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GPOR
GPOR
SRPT
SRPT
Q4 25
$398.2M
$369.6M
Q3 25
$379.7M
$370.0M
Q2 25
$447.6M
$513.1M
Q1 25
$197.0M
$611.5M
Q4 24
$239.9M
$638.2M
Q3 24
$253.9M
$429.8M
Q2 24
$181.1M
$360.5M
Q1 24
$283.2M
$359.5M
Net Profit
GPOR
GPOR
SRPT
SRPT
Q4 25
$132.4M
$-412.2M
Q3 25
$111.4M
$-50.6M
Q2 25
$184.5M
$196.9M
Q1 25
$-464.0K
$-447.5M
Q4 24
$-273.2M
$159.0M
Q3 24
$-14.0M
$33.6M
Q2 24
$-26.2M
$6.5M
Q1 24
$52.0M
$36.1M
Gross Margin
GPOR
GPOR
SRPT
SRPT
Q4 25
76.6%
Q3 25
74.6%
59.3%
Q2 25
80.7%
70.3%
Q1 25
57.9%
77.5%
Q4 24
63.2%
Q3 24
64.6%
78.7%
Q2 24
52.2%
87.6%
Q1 24
69.4%
85.9%
Operating Margin
GPOR
GPOR
SRPT
SRPT
Q4 25
44.9%
-111.4%
Q3 25
41.9%
-27.9%
Q2 25
56.0%
22.5%
Q1 25
6.1%
-49.1%
Q4 24
-131.3%
25.3%
Q3 24
5.7%
5.2%
Q2 24
-10.0%
-0.2%
Q1 24
28.9%
9.7%
Net Margin
GPOR
GPOR
SRPT
SRPT
Q4 25
33.3%
-111.5%
Q3 25
29.3%
-13.7%
Q2 25
41.2%
38.4%
Q1 25
-0.2%
-73.2%
Q4 24
-113.9%
24.9%
Q3 24
-5.5%
7.8%
Q2 24
-14.5%
1.8%
Q1 24
18.4%
10.0%
EPS (diluted)
GPOR
GPOR
SRPT
SRPT
Q4 25
$7.98
$-3.92
Q3 25
$4.45
$-0.50
Q2 25
$9.12
$1.89
Q1 25
$-0.07
$-4.60
Q4 24
$-14.72
$1.56
Q3 24
$-0.83
$0.34
Q2 24
$-1.51
$0.07
Q1 24
$2.34
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GPOR
GPOR
SRPT
SRPT
Cash + ST InvestmentsLiquidity on hand
$1.8M
$939.6M
Total DebtLower is stronger
$788.2M
$829.0M
Stockholders' EquityBook value
$1.8B
$1.1B
Total Assets
$3.0B
$3.3B
Debt / EquityLower = less leverage
0.43×
0.73×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GPOR
GPOR
SRPT
SRPT
Q4 25
$1.8M
$939.6M
Q3 25
$3.4M
$851.0M
Q2 25
$3.8M
$800.1M
Q1 25
$5.3M
$522.8M
Q4 24
$1.5M
$1.4B
Q3 24
$3.2M
$1.2B
Q2 24
$1.2M
$1.5B
Q1 24
$8.2M
$1.4B
Total Debt
GPOR
GPOR
SRPT
SRPT
Q4 25
$788.2M
$829.0M
Q3 25
$691.7M
$140.5M
Q2 25
$695.2M
Q1 25
$700.4M
Q4 24
$702.9M
$1.1B
Q3 24
$694.4M
$1.2B
Q2 24
$679.5M
$1.2B
Q1 24
$636.4M
$1.2B
Stockholders' Equity
GPOR
GPOR
SRPT
SRPT
Q4 25
$1.8B
$1.1B
Q3 25
$1.8B
$1.3B
Q2 25
$1.8B
$1.4B
Q1 25
$1.7B
$1.1B
Q4 24
$1.7B
$1.5B
Q3 24
$2.1B
$1.2B
Q2 24
$2.1B
$1.1B
Q1 24
$2.2B
$961.2M
Total Assets
GPOR
GPOR
SRPT
SRPT
Q4 25
$3.0B
$3.3B
Q3 25
$2.9B
$3.5B
Q2 25
$3.0B
$3.7B
Q1 25
$2.9B
$3.5B
Q4 24
$2.9B
$4.0B
Q3 24
$3.2B
$3.6B
Q2 24
$3.2B
$3.4B
Q1 24
$3.3B
$3.2B
Debt / Equity
GPOR
GPOR
SRPT
SRPT
Q4 25
0.43×
0.73×
Q3 25
0.38×
0.11×
Q2 25
0.39×
Q1 25
0.42×
Q4 24
0.41×
0.74×
Q3 24
0.34×
1.01×
Q2 24
0.32×
1.14×
Q1 24
0.29×
1.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GPOR
GPOR
SRPT
SRPT
Operating Cash FlowLast quarter
$185.4M
$131.2M
Free Cash FlowOCF − Capex
$127.6M
FCF MarginFCF / Revenue
34.5%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
1.40×
TTM Free Cash FlowTrailing 4 quarters
$-307.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GPOR
GPOR
SRPT
SRPT
Q4 25
$185.4M
$131.2M
Q3 25
$209.1M
$-14.6M
Q2 25
$231.4M
$261.3M
Q1 25
$177.3M
$-583.4M
Q4 24
$148.8M
$92.0M
Q3 24
$189.7M
$-70.7M
Q2 24
$123.5M
$14.9M
Q1 24
$188.0M
$-242.1M
Free Cash Flow
GPOR
GPOR
SRPT
SRPT
Q4 25
$127.6M
Q3 25
$-37.5M
Q2 25
$229.5M
Q1 25
$-627.1M
Q4 24
$54.0M
Q3 24
$-108.0M
Q2 24
$-14.2M
Q1 24
$-274.5M
FCF Margin
GPOR
GPOR
SRPT
SRPT
Q4 25
34.5%
Q3 25
-10.1%
Q2 25
44.7%
Q1 25
-102.5%
Q4 24
8.5%
Q3 24
-25.1%
Q2 24
-3.9%
Q1 24
-76.4%
Capex Intensity
GPOR
GPOR
SRPT
SRPT
Q4 25
1.0%
Q3 25
6.2%
Q2 25
6.2%
Q1 25
7.1%
Q4 24
6.0%
Q3 24
8.7%
Q2 24
8.1%
Q1 24
9.0%
Cash Conversion
GPOR
GPOR
SRPT
SRPT
Q4 25
1.40×
Q3 25
1.88×
Q2 25
1.25×
1.33×
Q1 25
Q4 24
0.58×
Q3 24
-2.10×
Q2 24
2.31×
Q1 24
3.61×
-6.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GPOR
GPOR

Natural Gas Production$296.9M75%
Other$42.7M11%
Naturalgasliquidsales$35.2M9%
Oil And Condensate$23.4M6%

SRPT
SRPT

Pmo Products$202.5M55%
Elevidys$110.4M30%
Other$56.7M15%

Related Comparisons